EIF2AK2 and Obesity: Further studies will be needed to determine if the chemical PKR inhibition might represent a valuable new therapeutic target to attenuate brain abnormal metabolic consequences linked to obesity and type 2 diabetes, afford neuroprotection and modulate cognitive decline in affected patients by neurodegenerative diseases such as AD.